|
Administration
Should be taken with food.
|
|
Special Precautions
Patient with sick sinus syndrome, bradycardia, or conduction defects; risk of ulcer disease; respiratory diseases (e.g. COPD, asthma); history of seizure disorder; bladder outlet obstruction, prostatic hyperplasia; body weight <50 kg. Mild to moderate hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may impair physical and mental abilities, if affected, do not drive or operate machinery. Monitoring Parameters Monitor cognitive function periodically; body weight, and symptoms of gastrointestinal intolerance.
|
|
Adverse Reactions
Significant: Allergic dermatitis (patch); CNS depression, extrapyramidal symptoms, nausea, vomiting, diarrhoea, anorexia, weight loss, decreased appetite, bradycardia, heart block.
Gastrointestinal disorders: Abdominal pain, dyspepsia.
General disorders and administration site conditions: Application site erythema, fatigue.
Injury, poisoning and procedural complications: Falling.
Nervous system disorders: Dizziness, headache, tremor, drowsiness, agitation, seizures.
Psychiatric disorders: Insomnia, confusion, depression.
|
|
Drug Interactions
Additive effect with succinylcholine-type muscle relaxants during anaesthesia; cholinometric substances (e.g. oxybutynin, tolterodine). Additive effect and increased risk of bradycardia with beta-blockers (e.g. atenolol). Increased risk of torsade de pointes with phenothiazines (e.g. chlorpromazine); benzamides (e.g. sulpiride, sultopride), pimozide, cisapride.
|
|
CIMS Class
|
|
ATC Classification
N06DA03 - rivastigmine ; Belongs to the class of anticholinesterases. Used in the management of dementia.
|
Sign Out
